There are some reports on the emergence of CSP resistant candidiasis upon preemptive therapy, as well as of isolates with reduced susceptibility to CSP during therapy, but as of yet, data on the frequency or the incidence of this secondary resistance is not yet available, although it will be very interesting to compare our in vitro data to it. The gene discussed is DNAJC5; the disease is candidiasis.